Equities analysts forecast that OraSure Technologies, Inc. (NASDAQ:OSUR) will report earnings per share of $0.07 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for OraSure Technologies’ earnings. OraSure Technologies also reported earnings per share of $0.07 during the same quarter last year. The company is expected to issue its next quarterly earnings report on Wednesday, August 2nd.
According to Zacks, analysts expect that OraSure Technologies will report full year earnings of $0.44 per share for the current fiscal year, with EPS estimates ranging from $0.40 to $0.47. For the next year, analysts expect that the firm will report earnings of $0.31 per share, with EPS estimates ranging from $0.30 to $0.31. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow OraSure Technologies.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.04. The business had revenue of $32.55 million during the quarter, compared to the consensus estimate of $31.19 million. OraSure Technologies had a net margin of 22.57% and a return on equity of 16.06%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.04 earnings per share.
A number of brokerages have recently weighed in on OSUR. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Saturday, May 6th. Jefferies Group LLC raised their target price on OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, May 4th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $12.04.
In related news, SVP Mark L. Kuna sold 36,413 shares of OraSure Technologies stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $15.11, for a total value of $550,200.43. Following the completion of the sale, the senior vice president now directly owns 92,904 shares in the company, valued at $1,403,779.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Douglas A. Michels sold 361,216 shares of OraSure Technologies stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $15.08, for a total value of $5,447,137.28. Following the completion of the sale, the chief executive officer now owns 881,620 shares of the company’s stock, valued at $13,294,829.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 929,859 shares of company stock valued at $13,926,644. Corporate insiders own 7.80% of the company’s stock.
A number of hedge funds have recently made changes to their positions in OSUR. Victory Capital Management Inc. purchased a new stake in shares of OraSure Technologies during the first quarter worth approximately $100,000. Boothbay Fund Management LLC bought a new position in shares of OraSure Technologies during the fourth quarter worth about $124,000. Private Advisor Group LLC boosted its position in shares of OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 723 shares during the period. Profund Advisors LLC bought a new position in shares of OraSure Technologies during the first quarter worth about $137,000. Finally, BNP Paribas Arbitrage SA boosted its position in shares of OraSure Technologies by 977.2% in the first quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock worth $139,000 after buying an additional 9,723 shares during the period. Hedge funds and other institutional investors own 88.02% of the company’s stock.
OraSure Technologies (NASDAQ OSUR) traded down 1.45% during midday trading on Tuesday, reaching $14.94. 1,115,137 shares of the company traded hands. OraSure Technologies has a 12-month low of $5.57 and a 12-month high of $15.90. The company has a market cap of $862.96 million, a price-to-earnings ratio of 28.62 and a beta of 1.60. The company has a 50-day moving average price of $14.85 and a 200-day moving average price of $11.52.
TRADEMARK VIOLATION NOTICE: This news story was published by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thestockobserver.com/2017/07/18/analysts-anticipate-orasure-technologies-inc-osur-will-post-earnings-of-0-07-per-share-updated-updated-updated.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.